AgingResearch.NewsJoin free

Ocugen

CompanyUnited StatesFounded 2006

ROR

Ocugen develops 7 assets, the furthest in phase 3 (OCU410 in dry age-related macular degeneration). Mostly gene therapy and small molecule acting on ADRA2A, ADRA2B and ADRA2C; based in the United States, founded in 2006.

7
Assets
Furthest stage
Phase 3
Raised
$98.6M
5
Trials
2
Signals

Pipeline

7

  • OCU410

    Delivers the RORA gene to retinal cells to regulate lipid metabolism, inflammation, and oxidative stress.

    Phase 3, Gene therapy, dry age-related macular degeneration, geographic atrophy (Phase 1)

  • brimonidine

    Brimonidine activates alpha-2 adrenergic receptors.

    Phase 2, no development reported, Small molecule, ADRA2A, ADRA2B, dry eye syndrome

  • OCU200

    Fusion protein targeting integrins to treat macular edema.

    Phase 1, Protein or enzyme, center-involved diabetic macular edema, diabetic macular edema

4 more assets

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms4
  • Trials5
  • Funding rounds and grants5
  • Deals26
  • Signals4
  • Similar companies6

Intelligence